
|Articles|November 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 11
- Volume 16
- Issue 11
Phase II trials planned for oral methylnaltrexone for chronic pain
Phase II trials planned for oral methylnaltrexone for chronic pain
Advertisement
COLLEGEVILLE, PennsylvaniaWyeth Pharmaceuticals and Progenics plan to initiate two 4-week phase II clinical trials to evaluate daily dosing of oral methylnaltrexone in patients with chronic, nonmalignant pain who are experiencing opioid-induced constipation (OIC). An NDA for the subcutaneous formulation has been filed with FDA for the treatment of OIC in the end-of-life setting.
Articles in this issue
almost 19 years ago
MT103, BiTE antibody, enters phase II testing for ALLalmost 19 years ago
Sides dig in as ESA policy debate heats upalmost 19 years ago
Ixempra gets ok for resistant breast canceralmost 19 years ago
ASCO adds Oncotype DX to marker guidelinealmost 19 years ago
Dr. Norton hopes to weed 'molecular' tumor gardenalmost 19 years ago
Accelerated approval for Tasignaalmost 19 years ago
Oxidative stress inducer ups survival in advanced melanomaalmost 19 years ago
FDA removes partial hold on Telcyta clinical developmentalmost 19 years ago
Should all HER2+ pts receive adjuvant trastuzumab?almost 19 years ago
R-CHOP is standard of care for advanced DLBCL patientsAdvertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
2
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
3
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
4
What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma
5





















































